2024
Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay
Liu M, Vathiotis I, Robbins C, Chan N, Moutafi M, Burela S, Xirou V, Schalper K, Herbst R, Syrigos K, Rimm D. Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay. Modern Pathology 2024, 37: 100556. PMID: 38964502, PMCID: PMC11416319, DOI: 10.1016/j.modpat.2024.100556.Peer-Reviewed Original ResearchNon-small cell lung cancerCases of non-small cell lung cancerNon-small cell lung cancer casesT-DXdCell lung cancerHER2 expressionBreast cancerRare case of non-small cell lung cancerQuantitative immunofluorescenceAntibody-drug conjugate trastuzumab deruxtecanLung cancerHER2 antibody-drug conjugatesNon-small cell lung cancer patientsDetecting HER2 expressionHER2-Targeted TherapyMetastatic breast cancerHER2 protein expressionBreast cancer casesHER2 protein levelsAntibody-drug conjugatesProportion of casesTrastuzumab deruxtecanNSCLC casesFrequency of casesImmunohistochemistry score
2023
Expression of cancer–testis antigens in the immune microenvironment of non‐small cell lung cancer
Hikmet F, Rassy M, Backman M, Méar L, Mattsson J, Djureinovic D, Botling J, Brunnström H, Micke P, Lindskog C. Expression of cancer–testis antigens in the immune microenvironment of non‐small cell lung cancer. Molecular Oncology 2023, 17: 2603-2617. PMID: 37341056, PMCID: PMC10701773, DOI: 10.1002/1878-0261.13474.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCancer-testis antigensCell lung cancerImmune microenvironmentLung cancerT cellsCTA expressionAnti-cancer immune responseMost NSCLC casesEfficacy of immunotherapyPlasma cell infiltrationRegulatory T cellsImmune cell densityCellular immune reactionsNSCLC patientsImmune profileClinical outcomesNSCLC casesCell infiltrationImmune cellsImmunohistochemical profilingM2 macrophagesClinical dataImmune responseImmune reactionsTissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test
Fernandez A, Gaule P, Rimm D. Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test. Modern Pathology 2023, 36: 100159. PMID: 36925070, PMCID: PMC10502188, DOI: 10.1016/j.modpat.2023.100159.Peer-Reviewed Original ResearchConceptsPD-L1 signalTumor proportion scoreTissue microarray cohortCell lung cancerPrevious clinical diagnosisWhole tissue sectionsCompanion diagnostic testsMultiple cancer typesMicroarray cohortTMA cohortLaboratory-developed testsPD-L1NSCLC casesLung cancerProportion scorePositive stainingAntibody 22C3Immunohistochemistry testsClinical diagnosisExtracellular domainCancer typesDiagnostic testsArchival tissueDomain antigenAntibodies
2022
Health outcomes modelling of RNA-based versus DNA-based detection of driver gene rearrangements in non-small cell lung cancer.
Jun T, Oh W, Schadt E, Higashi M. Health outcomes modelling of RNA-based versus DNA-based detection of driver gene rearrangements in non-small cell lung cancer. Journal Of Clinical Oncology 2022, 40: e18837-e18837. DOI: 10.1200/jco.2022.40.16_suppl.e18837.Peer-Reviewed Original ResearchQuality-adjusted life yearsTargeted therapyLung cancerNTRK1-3Gene rearrangementsLife yearsNon-small cell lung cancerMetastatic NSCLC casesTargeted therapy optionsCell lung cancerPopulation-level prevalence dataRNA-based methodsMetastatic NSCLCMET exonStable diseaseNSCLC casesSequencing panelTherapy optionsDNA-based methodsClinical impactFalse negativesHazard ratioNegative casesFDA approvalTherapy
2021
Somatic Mutation of BAP1 Can Lead to Expression Loss in Non-Small Cell Lung Carcinoma: Next Generation Sequencing and IHC Analysis in A Large Single Institute Cohort
Sun T, Wang X, Wang M, Minerowicz C, Sanchez H, Laskin W, Cohen P, Zhong M. Somatic Mutation of BAP1 Can Lead to Expression Loss in Non-Small Cell Lung Carcinoma: Next Generation Sequencing and IHC Analysis in A Large Single Institute Cohort. International Journal Of Surgical Pathology 2021, 30: 512-519. PMID: 34970936, DOI: 10.1177/10668969211070179.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaCell lung carcinomaLung carcinomaCell carcinomaSomatic mutationsClear cell renal cell carcinomaExpression lossCell renal cell carcinomaSquamous cell carcinomaNext-generation sequencingGenetic alterationsRenal cell carcinomaBAP1 protein expressionProtein expression statusStudy cohortNSCLC casesNSCLC tumorsLoss of expressionNeural tumorsAdditional genetic alterationsCommon findingIHC analysisNSCLC carcinogenesisIRB approvalMelanocytic tumorsInfiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer
Backman M, La Fleur L, Kurppa P, Djureinovic D, Elfving H, Brunnström H, Mattsson J, Lindberg A, Pontén V, Eltahir M, Mangsbo S, Gulyas M, Isaksson J, Jirström K, Kärre K, Leandersson K, Mezheyeuski A, Pontén F, Strell C, Lindskog C, Botling J, Micke P. Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer. The Journal Of Pathology 2021, 255: 243-256. PMID: 34339045, DOI: 10.1002/path.5772.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerImmune cell infiltrationHigh immune cell infiltrationCell infiltrationNK cellsImmune classPlasma cellsLow immune cell infiltrationEra of immunotherapyCell lung cancerImmune cell markersTumor mutational loadImmune response-related genesInnate immune responseImmune cell analysisClinicopathologic characteristicsPD-L1Immune activationImmune classificationNSCLC casesImmune patternsLung cancerImmune cellsClinical backgroundImmune response
2020
Development of a serum miRNA panel for detection of early stage non-small cell lung cancer
Ying L, Du L, Zou R, Shi L, Zhang N, Jin J, Xu C, Zhang F, Zhu C, Wu J, Chen K, Huang M, Wu Y, Zhang Y, Zheng W, Pan X, Chen B, Lin A, Tam J, van Dam R, Lai D, Chia K, Zhou L, Too H, Yu H, Mao W, Su D. Development of a serum miRNA panel for detection of early stage non-small cell lung cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 25036-25042. PMID: 32943537, PMCID: PMC7547174, DOI: 10.1073/pnas.2006212117.Peer-Reviewed Original ResearchConceptsNonsmall cell lung cancerCell lung cancerMinimally invasive testArea under curveLung cancerInvasive testingEarly stage NSCLCEarly stage non-small cell lung cancerNonsmall cell lung cancer casesNonsmall cell lung cancer detectionStage non-small cell lung cancerStage nonsmall cell lung cancerSerum miRNA panelsNon-small cell lung cancerSmoking statusStage I NSCLCIndependent of smoking statusImprove patient survivalEarly detectionEarly detection of lung cancerUnmet clinical needDetection of lung cancerCase-control cohortMiRNA panelNSCLC casesBiomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling
Zugazagoitia J, Gupta S, Liu Y, Fuhrman K, Gettinger S, Herbst RS, Schalper KA, Rimm DL. Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling. Clinical Cancer Research 2020, 26: 4360-4368. PMID: 32253229, PMCID: PMC7442721, DOI: 10.1158/1078-0432.ccr-20-0175.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPD-1 checkpoint blockadeCell lung cancerCheckpoint blockadeLung cancerAdvanced non-small cell lung cancerUnivariate unadjusted analysisProgression-free survivalImmune cell countsMinority of patientsRobust predictive biomarkersBiomarkers of responseLarge independent cohortsSpatial profiling technologyDigital spatial profilingDigital spatial profiling (DSP) technologyOverall survivalClinical outcomesImmune predictorsHigher CD56NSCLC casesPredictive biomarkersUnadjusted analysesImmune parametersTissue microarray
2018
Multispectral imaging for quantitative and compartment‐specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients
Mezheyeuski A, Bergsland C, Backman M, Djureinovic D, Sjöblom T, Bruun J, Micke P. Multispectral imaging for quantitative and compartment‐specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients. The Journal Of Pathology 2018, 244: 421-431. PMID: 29282718, DOI: 10.1002/path.5026.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, Non-Small-Cell LungClinical Decision-MakingDeep LearningFluorescent Antibody TechniqueHumansImage Interpretation, Computer-AssistedLung NeoplasmsLymphocyte SubsetsLymphocytes, Tumor-InfiltratingMicroscopy, FluorescencePredictive Value of TestsPrognosisReproducibility of ResultsSequence Analysis, RNATissue Array AnalysisTumor MicroenvironmentConceptsImmune infiltratesImmune markersImmune cellsImmunohistochemical methodsEra of immunotherapyCell lung cancerImmune cell infiltrationLymphocyte subclassesNSCLC casesCell infiltrationLung cancerPatient prognosisImmune responseTissue microarrayCancer tissuesStromal compartmentClinical decisionFurther subpopulationSemiquantitative assessmentConventional immunohistochemistryImmunohistochemistryClinical biopsiesTissue sectionsFoxp3CD4
2016
Profiling cancer testis antigens in non–small-cell lung cancer
Djureinovic D, Hallström B, Horie M, Mattsson J, La Fleur L, Fagerberg L, Brunnström H, Lindskog C, Madjar K, Rahnenführer J, Ekman S, Ståhle E, Koyi H, Brandén E, Edlund K, Hengstler J, Lambe M, Saito A, Botling J, Pontén F, Uhlén M, Micke P. Profiling cancer testis antigens in non–small-cell lung cancer. JCI Insight 2016, 1: e86837. PMID: 27699219, PMCID: PMC5033889, DOI: 10.1172/jci.insight.86837.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerCancer testisCTA expressionDifferent normal organsProtein expressionCancer Genome AtlasImmunotherapeutic strategiesPrognostic impactNSCLC casesNSCLC tissuesSurvival associationsNew CTANormal organsBiomarker studiesClinical interestCancerGenome AtlasReliable CTACTANSCLCConcurrent expressionRNAseq dataValuable targetStringent criteriaLung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base. Journal Of Thoracic Oncology 2016, 11: 1121-1131. PMID: 27103511, DOI: 10.1016/j.jtho.2016.03.023.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer Data BaseYounger patientsOlder patientsLung cancerRelative survivalStage IAdvanced stage non-small cell lung cancerCell lung cancerYears of ageAggressive therapyAggressive treatmentOverall survivalPatient demographicsPrimary outcomeTreatment patternsTumor characteristicsNSCLC casesPatientsStage IIIDetailed stagingSurvival informationOlder groupDistinct subsetsCancer
2013
Programmed death ligand-1 expression in non-small cell lung cancer
Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Laboratory Investigation 2013, 94: 107-116. PMID: 24217091, PMCID: PMC6125250, DOI: 10.1038/labinvest.2013.130.Peer-Reviewed Original ResearchMeSH KeywordsAgedB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell Line, TumorChi-Square DistributionCohort StudiesConnecticutFemaleGreeceHumansImmunohistochemistryLung NeoplasmsLymphocytes, Tumor-InfiltratingMalePrognosisReproducibility of ResultsRNA, MessengerSurvival AnalysisTissue Array AnalysisConceptsNon-small cell lung cancerPD-L1 expressionCell lung cancerPD-L1Tissue microarrayBetter outcomesNSCLC casesLung cancerDeath ligand 1 (PD-L1) expressionCell death ligand 1PD-L1 protein expressionEarly phase clinical trialsLigand 1 expressionTumor-infiltrating lymphocytesDeath ligand 1Significant better outcomePD-L1 mRNAPD-L1 proteinPhase clinical trialsNormal human placentaPrediction of responseQuantitative fluorescence approachesFrequency of expressionPD-1Prognostic valueClinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC).
Velcheti V, Schalper K, Carvajal D, Chen L, Sznol M, Gettinger S, Herbst R, Rimm D. Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: 11075-11075. DOI: 10.1200/jco.2013.31.15_suppl.11075.Peer-Reviewed Original ResearchNon-small cell lung cancerTumor-infiltrating lymphocytesPresence of TILsGreek cohortBetter outcomesPDL1 expressionNSCLC casesProtein positivityAnti-PD-1 therapyDeath ligand 1 (PD-L1) expressionCell death ligand 1Quantitative immunofluorescenceComparable prognostic informationIndependent NSCLC cohortsPDL1 protein expressionLigand 1 expressionLonger overall survivalPDL1 mRNADeath ligand 1Cell lung cancerMRNA levelsAQUA methodNormal human placentaNSCLC cohortOverall survival
2010
Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk
Qian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer 2010, 73: 138-146. PMID: 21195504, DOI: 10.1016/j.lungcan.2010.11.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungDNA RepairDNA Repair EnzymesDNA-Binding ProteinsFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansLung NeoplasmsMaleMiddle AgedPolymorphism, GeneticRisk FactorsSmokingXeroderma Pigmentosum Group A ProteinXeroderma Pigmentosum Group D ProteinYoung AdultConceptsNon-small cell lung cancerLung cancer riskSquamous cell carcinomaLung cancerCancer riskCell carcinomaSingle nucleotide polymorphismsHigh riskGenetic polymorphismsNon-small cell lung cancer riskRisk of NSCLCCell lung cancer riskHigher lung cancer riskCell lung cancerVariant AA genotypeDominant risk factorNumerous epidemiological studiesLogistic regression modelsDNA repair pathway genesYoung smokersNSCLC casesSubgroup analysisRisk factorsHealthy controlsStratified analysis
2008
A SNP in a let-7 microRNA Complementary Site in the KRAS 3′ Untranslated Region Increases Non–Small Cell Lung Cancer Risk
Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB. A SNP in a let-7 microRNA Complementary Site in the KRAS 3′ Untranslated Region Increases Non–Small Cell Lung Cancer Risk. Cancer Research 2008, 68: 8535-8540. PMID: 18922928, PMCID: PMC2672193, DOI: 10.1158/0008-5472.can-08-2129.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCase-control studyLung cancer riskIndependent case-control studiesLung cancerSingle nucleotide polymorphismsCancer riskNon-small cell lung cancer riskCell lung cancer riskVariant allelesCell lung cancerKRAS 3' untranslated regionLung cancer susceptibilityUnidentified single-nucleotide polymorphismsNSCLC patientsModerate smokersNSCLC cancerNSCLC casesCancer deathKRAS overexpressionCancerCancer susceptibilityOncogene expressionPatientsRisk
2007
Clinical implications of tumor cavitation following therapy with angiogenesis inhibitors in non-small cell lung cancer (NSCLC) patients
Onn A, Martinez C, Herbst R, Riddle J, Blumenschein G, Stewart D, Marom E. Clinical implications of tumor cavitation following therapy with angiogenesis inhibitors in non-small cell lung cancer (NSCLC) patients. Journal Of Clinical Oncology 2007, 25: 18034-18034. DOI: 10.1200/jco.2007.25.18_suppl.18034.Peer-Reviewed Original ResearchTumor cavitationLung cancer patientsAntiangiogenic agentsCancer patientsAngiogenesis inhibitorsNon-small cell lung cancer patientsClinical implicationsMedian progression-free survivalCell lung cancer patientsMD Anderson Cancer CenterProgression-free survivalSoft tissue densityAnderson Cancer CenterPrevious chemotherapyStable diseaseAdverse eventsNSCLC patientsAdvanced cancerCancer CenterNSCLC casesLung cancerPrimary tumorMedical recordsSubsegmental arteriesClinical data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply